Premium
LONG‐TERM ADMINISTRATION OF MEDROXY‐PROGESTERONE ACETATE (MPA) TO ACROMEGALIC PATIENTS
Author(s) -
JOSEFSBERG Z.,
LARON Z.,
MATHIAS Sh.,
KERET R.
Publication year - 1974
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1974.tb01795.x
Subject(s) - medroxyprogesterone acetate , acromegaly , endocrinology , medicine , medroxyprogesterone , growth hormone , hyperinsulinism , hormone , insulin , insulin resistance
SUMMARY The long‐term administration of medroxyprogesterone acetate (MPA), 40 mg/day, has not proved to be an effective treatment of acromegaly. It neither stops the growth of the tumour nor adequately suppresses growth hormone secretion and it brings no change in the glucose intolerance and hyperinsulinism.